{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:28:22Z","timestamp":1789698502658,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R61NS119639"],"award-info":[{"award-number":["R61NS119639"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001625","name":"Foundation to Eradicate Duchenne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.steroids.2025.109689","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:15:16Z","timestamp":1757909716000},"page":"109689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials"],"prefix":"10.1016","volume":"223","author":[{"given":"Ana","family":"de Vera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh J","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Gresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir","family":"Hasham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Damsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Wahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.steroids.2025.109689_b0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3233\/JND-221575","article-title":"Functional and clinical outcomes associated with steroid treatment among non-ambulatory patients with duchenne muscular dystrophy1","volume":"10","author":"McDonald","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.steroids.2025.109689_b0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of duchenne muscular dystrophy: Report of the guideline development subcommittee of the american academy of neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: First approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0025","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","volume":"2","author":"Heier","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.steroids.2025.109689_b0030","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"39","key":"10.1016\/j.steroids.2025.109689_b0035","doi-asserted-by":"crossref","first-page":"24285","DOI":"10.1073\/pnas.2006890117","article-title":"Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment","volume":"117","author":"Liu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.steroids.2025.109689_b0040","doi-asserted-by":"crossref","unstructured":"A. Crastin et al., Vamorolone: A novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects, Rheumatology (Oxford), Apr 2 2025, doi: 10.1093\/rheumatology\/keaf129.","DOI":"10.1093\/rheumatology\/keaf129"},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","article-title":"11beta-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.steroids.2025.109689_b0050","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1210\/jc.2003-022025","article-title":"11beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone","volume":"88","author":"Cooper","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"15","key":"10.1016\/j.steroids.2025.109689_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22157828","article-title":"Global deletion of 11beta-HSD1 prevents muscle wasting associated with glucocorticoid therapy in polyarthritis","volume":"22","author":"Webster","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.steroids.2025.109689_b0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0065","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1532-429X-15-107","article-title":"Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: Effect of age and left ventricular systolic function","volume":"15","author":"Hor","year":"2013","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13023-021-01862-w","article-title":"The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: A systematic literature review","volume":"16","author":"Szabo","year":"2021","journal-title":"Orphanet. J. Rare. Dis."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010356","article-title":"Role of the renin-angiotensin-aldosterone system in dystrophin-deficient cardiomyopathy","volume":"22","author":"Rodriguez-Gonzalez","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.steroids.2025.109689_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103186","article-title":"Duchenne dilated cardiomyopathy: Cardiac management from prevention to advanced cardiovascular therapies","volume":"9","author":"Adorisio","year":"2020","journal-title":"J Clin. Med."},{"issue":"2","key":"10.1016\/j.steroids.2025.109689_b0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: A randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.steroids.2025.109689_b0090","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1542\/peds.2018-0333I","article-title":"Cardiac management of the patient with duchenne muscular dystrophy","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: A 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.steroids.2025.109689_b0100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: A randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.steroids.2025.109689_b0105","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: A randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.steroids.2025.109689_b0110","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.steroids.2025.109689_b0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpdd.855","article-title":"Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers","volume":"10","author":"Nakamura","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"7","key":"10.1016\/j.steroids.2025.109689_b0120","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","article-title":"Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator","volume":"84","author":"Erlandsson","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.steroids.2025.109689_b0130","unstructured":"D. Sabanes Bove et al., mmrm: Mixed Models for Repeated Measures. R package version 0.3.14, ed, 2024."},{"issue":"7","key":"10.1016\/j.steroids.2025.109689_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucl. Acids Res."},{"issue":"15","key":"10.1016\/j.steroids.2025.109689_b0140","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1042\/CS20201453","article-title":"Klotho and calciprotein particles as therapeutic targets against accelerated ageing","volume":"135","author":"Kuro","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.steroids.2025.109689_b0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-9-180","article-title":"The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism","volume":"9","author":"Eudy","year":"2011","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.steroids.2025.109689_b0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2125.1976.tb00624.x","article-title":"The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects","volume":"3","author":"Ramsay","year":"1976","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.steroids.2025.109689_b0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2125.1982.tb01413.x","article-title":"Spironolactone dose-response relationships in healthy subjects","volume":"13","author":"McInnes","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.steroids.2025.109689_b0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.steroids.2025.109689_b0165","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J. Hypertens."},{"issue":"14","key":"10.1016\/j.steroids.2025.109689_b0170","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.steroids.2025.109689_b0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): A systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","journal-title":"Heart Fail. Rev."},{"issue":"2","key":"10.1016\/j.steroids.2025.109689_b0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF","volume":"77","author":"Naser","year":"2023","journal-title":"Med. Arch."},{"issue":"12","key":"10.1016\/j.steroids.2025.109689_b0185","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s40262-023-01312-9","article-title":"The pharmacokinetics of the nonsteroidal mineralocorticoid receptor antagonist finerenone","volume":"62","author":"Heinig","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"27","key":"10.1016\/j.steroids.2025.109689_b0190","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.steroids.2025.109689_b0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2125.1984.tb02478.x","article-title":"Metabolic effects of high dose amiloride and spironolactone: A comparative study in normal subjects","volume":"18","author":"Millar","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.steroids.2025.109689_b0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2004.03146.x","article-title":"Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"6","author":"Saruta","year":"2004","journal-title":"J. Clin. Hypertens (Greenwich)"},{"key":"10.1016\/j.steroids.2025.109689_b0205","article-title":"Pathobiology of the Klotho antiaging protein and therapeutic considerations","volume":"3","author":"Prud'homme","year":"2022","journal-title":"Front. Aging"},{"issue":"11","key":"10.1016\/j.steroids.2025.109689_b0210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"issue":"20","key":"10.1016\/j.steroids.2025.109689_b0215","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1007\/s00018-008-8177-0","article-title":"The discovery of alpha-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis","volume":"65","author":"Nabeshima","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.steroids.2025.109689_b0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1089\/rej.2013.1523","article-title":"Association of Klotho polymorphisms with healthy aging: A systematic review and meta-analysis","volume":"17","author":"Di Bona","year":"2014","journal-title":"Rejuvenation Res."},{"issue":"4","key":"10.1016\/j.steroids.2025.109689_b0225","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.ymthe.2025.02.030","article-title":"Long-term effects of s-KL treatment in wild-type mice: Enhancing longevity, physical well-being, and neurological resilience","volume":"33","author":"Roig-Soriano","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.steroids.2025.109689_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.945287","article-title":"The structure, biosynthesis, and biological roles of fetuin-a: A review","volume":"10","author":"Chekol Abebe","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"issue":"Suppl 3","key":"10.1016\/j.steroids.2025.109689_b0235","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: Pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.steroids.2025.109689_b0240","unstructured":"E. M. Agency, \u201cAGAMREE (vamorolone) oral suspension \u201d, ed: AGAMREE (vamorolone) oral suspension Summary of Product Characteristics. Pratteln, Switzerland: Santhera Pharmaceuticals (Switzerland) Ltd."},{"key":"10.1016\/j.steroids.2025.109689_b0245","unstructured":"U. S. o. A. F. a. D. Administration, \u201cAgamree (vamorolone) oral suspension prescribing information,\u201d www.accessdata.fda.gov, 2023. [Online]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215239s000lbl.pdf."},{"issue":"1","key":"10.1016\/j.steroids.2025.109689_b0250","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s13023-024-03372-x","article-title":"Predictors of cardiac disease in duchenne muscular dystrophy: A systematic review and evidence grading","volume":"19","author":"Landfeldt","year":"2024","journal-title":"Orphanet. J. Rare. Dis."},{"issue":"9","key":"10.1016\/j.steroids.2025.109689_b0255","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","article-title":"All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy","volume":"61","author":"Schram","year":"2013","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X25001308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X25001308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:14:28Z","timestamp":1773116068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X25001308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"alternative-id":["S0039128X25001308"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2025.109689","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2025.109689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109689"}}